ONY Biotech is dedicated to developing innovative therapies aimed at improving respiratory health in newborns, particularly through its flagship product, Infasurf® (calfactant). This surfactant is specifically designed to prevent and treat Neonatal Respiratory Distress Syndrome (RDS), a condition that often affects premature infants due to underdeveloped lungs and insufficient surfactant production. Infasurf® works by restoring surface activity in the lungs, thereby enhancing respiration and significantly improving outcomes for vulnerable newborns. Since its FDA approval in 1998, Infasurf® has been instrumental in supporting the health of premature infants across 27 countries.

In addition to its commercial products, ONY Biotech actively engages in research and development through its Investigator-Initiated Research program. This initiative supports various research projects that aim to advance medical knowledge related to their therapies, including studies on alternative administration methods for Infasurf® and its potential as a delivery medium for other drugs. The company provides flexible funding to researchers, facilitating both preclinical and early clinical development activities. This commitment to research not only enhances the understanding of their products but also fosters innovation in neonatal care, ultimately benefiting the smallest and most vulnerable patients.

United States

A small, privately-held, and family-focused neonatology pharmaceutical company, ONY Biotech is a leader in the creation of critically important products for the treatment of premature infants. We innovate with a singular purpose: to improve outcomes for premature babies and their families.

As a USA-born neonatology biotech, we take pride in the work we do delivering treatments that serve families here in the United States and around the world.

Ony Biotech

Company Details